Atossa Q3 2023: cash $94M; two Phase 2 trials 80% enrolled; net loss details

ATOSSA THERAPEUTICS, INC.

2024-Q3 EPS reported -$0.18

Cash and cash equivalents $94.0M as of Sept 30, 2023.
Two Phase 2 trials (Karisma-Endoxifen, I-SPY 2) at 80% enrollment; data expected H2 2024.
R&D expense $4.5M in Q3 2023, down 13% YoY; G&A $3.0M, flat YoY.
Interest income $1.3M in Q3 2023 vs $0.2M in Q3 2022 due to higher rates and balance.
Jonathan Finn appointed to Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

ATOSSA THERAPEUTICS, INC. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended September 30, 2023 financial results and a Company update.

View on SEC.gov

Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-031420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.